Altitude sickness

Altitude sickness
Other names: High-altitude sickness,[1] altitude illness,[1] hypobaropathy, altitude bends, soroche
Sign displays "Caution! You are at 17586 ft (5360 m)"
Altitude sickness warning – Indian Army
SpecialtyEmergency medicine
SymptomsHeadache, vomiting, feeling tired, trouble sleeping, dizziness[1]
ComplicationsHigh altitude pulmonary edema (HAPE),
high altitude cerebral edema (HACE)[1]
Usual onsetWithin 24 hours[1]
TypesAcute mountain sickness, high altitude pulmonary edema, high altitude cerebral edema, chronic mountain sickness[2]
CausesLow amounts of oxygen at high elevation[1][2]
Risk factorsPrior episode, high degree of activity, rapid increase in elevation[2]
Diagnostic methodBased on symptoms[2]
Differential diagnosisExhaustion, viral infection, hangover, dehydration, carbon monoxide poisoning[1]
PreventionGradual ascent[1]
TreatmentDescent to lower altitude, sufficient fluids[1][2]
MedicationIbuprofen, acetazolamide, dexamethasone, oxygen therapy[2]
Frequency20% at 2,500 metres (8,000 ft)
40% at 3,000 metres (10,000 ft)[1][2]

Altitude sickness, the mildest form being acute mountain sickness (AMS), is the negative health effect of high altitude, caused by rapid exposure to low amounts of oxygen at high elevation.[1][2] Symptoms may include headaches, vomiting, tiredness, trouble sleeping, and dizziness.[1] Acute mountain sickness can progress to high altitude pulmonary edema (HAPE) with associated shortness of breath or high altitude cerebral edema (HACE) with associated confusion.[1][2] Chronic mountain sickness may occur after long term exposure to high altitude.[2]

Altitude sickness typically occurs only above 2,500 metres (8,000 ft), though some are affected at lower altitudes.[2][3] Risk factors include a prior episode of altitude sickness, a high degree of activity, and a rapid increase in elevation.[2] Diagnosis is based on symptoms and is supported in those who have more than a minor reduction in activities.[2][4] It is recommended that at high-altitude any symptoms of headache, nausea, shortness of breath, or vomiting be assumed to be altitude sickness.[5]

Prevention is by gradually increasing elevation by no more than 300 metres (1,000 ft) per day.[1] Being physically fit does not decrease the risk.[2] Treatment is generally by descending to a lower altitude and sufficient fluids.[1][2] Mild cases may be helped by ibuprofen, acetazolamide, or dexamethasone.[2] Severe cases may benefit from oxygen therapy and a portable hyperbaric bag may be used if descent is not possible.[1] Treatment efforts, however, have not been well studied.[3]

AMS occurs in about 20% of people after rapidly going to 2,500 metres (8,000 ft) and 40% of people going to 3,000 metres (10,000 ft).[1][2] While AMS and HACE occurs equally frequently in males and females, HAPE occurs more often in males.[1] The earliest description of altitude sickness is attributed to a Chinese text from around 30 BCE which describes "Big Headache Mountains" possibly referring to the Karakoram Mountains around Kilik Pass.[6]

Signs and symptoms

Right: A woman with a swollen face while trekking at high altitude (Annapurna Base Camp, Nepal; 4130 m). Left: The same woman at normal altitude.

People have different susceptibilities to altitude sickness; for some otherwise healthy people, acute altitude sickness can begin to appear at around 2,000 metres (6,600 ft) above sea level, such as at many mountain ski resorts, equivalent to a pressure of 80 kilopascals (0.79 atm).[7] This is the most frequent type of altitude sickness encountered. Symptoms often manifest themselves six to ten hours after ascent and generally subside in one to two days, but they occasionally develop into the more serious conditions. Symptoms include headache, fatigue, stomach illness, dizziness, and sleep disturbance.[8] Exertion aggravates the symptoms.

Those individuals with the lowest initial partial pressure of end-tidal pCO2 (the lowest concentration of carbon dioxide at the end of the respiratory cycle, a measure of a higher alveolar ventilation) and corresponding high oxygen saturation levels tend to have a lower incidence of acute mountain sickness than those with high end-tidal pCO2 and low oxygen saturation levels.[9]

Primary symptoms

Headaches are the primary symptom used to diagnose altitude sickness, although a headache is also a symptom of dehydration. A headache occurring at an altitude above 2,400 metres (7,900 ft) – a pressure of 76 kilopascals (0.75 atm) – combined with any one or more of the following symptoms, may indicate altitude sickness:

Disordered System Symptoms
Gastrointestinal Loss of appetite, nausea, or vomiting, excessive flatulation[10]
Nervous Fatigue or weakness, headache with or without dizziness or lightheadedness, insomnia, “pins and needles” sensation
Locomotory Peripheral edema (swelling of hands, feet, and face)
Respiratory Nose bleeding, shortness of breath upon exertion
Cardiovascular Persistent rapid pulse
Other General malaise

Severe symptoms

Symptoms that may indicate life-threatening altitude sickness include:

Pulmonary edema (fluid in the lungs)
Symptoms similar to bronchitis
Persistent dry cough
Fever
Shortness of breath even when resting
Cerebral edema (swelling of the brain)
Headache that does not respond to analgesics
Unsteady gait
Gradual loss of consciousness
Increased nausea and vomiting
Retinal hemorrhage

The most serious symptoms of altitude sickness arise from edema (fluid accumulation in the tissues of the body). At very high altitude, humans can get either high altitude pulmonary edema (HAPE), or high altitude cerebral edema (HACE). The physiological cause of altitude-induced edema is not conclusively established. It is currently believed, however, that HACE is caused by local vasodilation of cerebral blood vessels in response to hypoxia, resulting in greater blood flow and, consequently, greater capillary pressures. On the other hand, HAPE may be due to general vasoconstriction in the pulmonary circulation (normally a response to regional ventilation-perfusion mismatches) which, with constant or increased cardiac output, also leads to increases in capillary pressures. For those suffering HACE, dexamethasone may provide temporary relief from symptoms in order to keep descending under their own power.

HAPE can progress rapidly and is often fatal. Symptoms include fatigue, severe dyspnea at rest, and cough that is initially dry but may progress to produce pink, frothy sputum. Descent to lower altitudes alleviates the symptoms of HAPE.

HACE is a life-threatening condition that can lead to coma or death. Symptoms include headache, fatigue, visual impairment, bladder dysfunction, bowel dysfunction, loss of coordination, paralysis on one side of the body, and confusion. Descent to lower altitudes may save those afflicted with HACE.

Cause

See also: Breathing § Breathing at altitude, and Effects of high altitude on humans
Climbers on Mount Everest often experience altitude sickness.

Altitude sickness can first occur at 1,500 metres, with the effects becoming severe at extreme altitudes (greater than 5,500 metres). Only brief trips above 6,000 metres are possible and supplemental oxygen is needed to avert sickness.

As altitude increases, the available amount of oxygen to sustain mental and physical alertness decreases with the overall air pressure, though the relative percentage of oxygen in air, at about 21%, remains practically unchanged up to 21,000 metres (70,000 ft).[11] The RMS velocities of diatomic nitrogen and oxygen are very similar and thus no change occurs in the ratio of oxygen to nitrogen until stratospheric heights.

Dehydration due to the higher rate of water vapor lost from the lungs at higher altitudes may contribute to the symptoms of altitude sickness.[12]

The rate of ascent, altitude attained, amount of physical activity at high altitude, as well as individual susceptibility, are contributing factors to the onset and severity of high-altitude illness.

Altitude sickness usually occurs following a rapid ascent and can usually be prevented by ascending slowly.[8] In most of these cases, the symptoms are temporary and usually abate as altitude acclimatization occurs. However, in extreme cases, altitude sickness can be fatal.

High altitude

At high altitude, 1,500 to 3,500 metres (4,900 to 11,500 ft), the onset of physiological effects of diminished inspiratory oxygen pressure (PiO2) includes decreased exercise performance and increased ventilation (lower arterial partial pressure of carbon dioxide: PCO2). While arterial oxygen transport may be only slightly impaired the arterial oxygen saturation (SaO2) generally stays above 90%. Altitude sickness is common between 2,400 and 4,000 m because of the large number of people who ascend rapidly to these altitudes.[10]

Very high altitude

At very high altitude, 3,500 to 5,500 metres (11,500 to 18,000 ft), maximum SaO2 falls below 90% as the arterial PO2 falls below 60mmHg. Extreme hypoxemia may occur during exercise, during sleep, and in the presence of high altitude pulmonary edema or other acute lung conditions. Severe altitude illness occurs most commonly in this range.[10]

Extreme altitude

Above 5,500 metres (18,000 ft), marked hypoxemia, hypocapnia, and alkalosis are characteristic of extreme altitudes. Progressive deterioration of physiologic function eventually outstrips acclimatization. As a result, no permanent human habitation occurs above 6,000 metres (20,000 ft). A period of acclimatization is necessary when ascending to extreme altitude; abrupt ascent without supplemental oxygen for other than brief exposures invites severe altitude sickness.[10]

Mechanism

The physiology of altitude sickness centres around the alveolar gas equation; the atmospheric pressure is low, but there is still 20.9% Oxygen. Water vapour still occupies the same pressure too—this means that there is less oxygen pressure available in the lungs and blood. Compare these two equations comparing the amount of oxygen in blood at altitude:[13]

At Sea Level At 8400 m (The Balcony of Everest) Formula
Pressure of oxygen in the alveolus 21%.(101.3 kPa-6.3 kPa) - (5.3 kPa/0.8 kPa) = 13.3 kPa O2 21%.(36.3 kPa-6.3 kPa) - (1.8 kPa/0.74 kPa) = 3.9 kPa O2 FIO2.(PB-PH2O)-(PCO2/RQ)
Oxygen Carriage in the blood (0.98 * 1.34 * 14 g/dL) + (0.023 x 12 kPa)
= 17.3 ml O2 / 100 ml Blood		 (0.54 * 1.34 * 19.3 g/dL) + (0.023 x 3.3 kPa)
= 14.0 ml O2 / 100 ml Blood		 (SaO2 * 1.34 ml/g Hb * Hb)
+ (Oxygen carriage in blood * PaO2)

The hypoxia leads to an increase in minute ventilation (hence both low CO2, and subsequently bicarbonate), Hb increases through haemoconcentration and erythrogenesis. Alkalosis shifts the haemoglobin dissociation constant to the left, 2,3-BPG increases to counter this. Cardiac output increases through an increase in heart rate.[13]

The body's response to high altitude includes the following:[13]

  • ↑ Erythropoietin → ↑ hematocrit and haemoglobin
  • ↑ 2,3-BPG (allows ↑ release of O2 and a right shift on the Hb-O2 disassociation curve)
  • ↑ kidney excretion of bicarbonate (use of acetazolamide can augment for treatment)
  • Chronic hypoxic pulmonary vasoconstriction (can cause right ventricular hypertrophy)

People with high-altitude sickness generally have reduced hyperventilator response, impaired gas exchange, fluid retention or increased sympathetic drive. There is thought to be an increase in cerebral venous volume because of an increase in cerebral blood flow and hypocapnic cerebral vasoconstriction causing oedema.[13]

Diagnosis

Diagnosis can be assisted with a number of different scoring systems.[4]

Prevention

Ascending slowly is the best way to avoid altitude sickness.[8] Avoiding strenuous activity such as skiing, hiking, etc. in the first 24 hours at high altitude reduces the symptoms of AMS. Alcohol and sleeping pills are respiratory depressants, and thus slow down the acclimatization process and should be avoided. Alcohol also tends to cause dehydration and exacerbates AMS. Thus, avoiding alcohol consumption in the first 24–48 hours at a higher altitude is optimal.

Pre-acclimatization

Pre-acclimatization is when the body develops tolerance to low oxygen concentrations before ascending to an altitude. It significantly reduces risk because less time has to be spent at altitude to acclimatize in the traditional way. Additionally, because less time has to be spent on the mountain, less food and supplies have to be taken up. Several commercial systems exist that use altitude tents, so called because they mimic altitude by reducing the percentage of oxygen in the air while keeping air pressure constant to the surroundings.

Acclimatization

Altitude acclimatization is the process of adjusting to decreasing oxygen levels at higher elevations, in order to avoid altitude sickness.[14] Once above approximately 3,000 metres (10,000 ft) – a pressure of 70 kilopascals (0.69 atm) – most climbers and high-altitude trekkers take the "climb-high, sleep-low" approach. For high-altitude climbers, a typical acclimatization regimen might be to stay a few days at a base camp, climb up to a higher camp (slowly), and then return to base camp. A subsequent climb to the higher camp then includes an overnight stay. This process is then repeated a few times, each time extending the time spent at higher altitudes to let the body adjust to the oxygen level there, a process that involves the production of additional red blood cells.[15] Once the climber has acclimatized to a given altitude, the process is repeated with camps placed at progressively higher elevations. The rule of thumb is to ascend no more than 300 m (1,000 ft) per day to sleep. That is, one can climb from 3,000 m (9,800 ft) (70 kPa or 0.69 atm) to 4,500 m (15,000 ft) (58 kPa or 0.57 atm) in one day, but one should then descend back to 3,300 m (10,800 ft) (67.5 kPa or 0.666 atm) to sleep. This process cannot safely be rushed, and this is why climbers need to spend days (or even weeks at times) acclimatizing before attempting to climb a high peak. Simulated altitude equipment such as altitude tents provide hypoxic (reduced oxygen) air, and are designed to allow partial pre-acclimation to high altitude, reducing the total time required on the mountain itself.

Altitude acclimatization is necessary for some people who move rapidly from lower altitudes to intermediate altitudes (e.g., by aircraft and ground transportation over a few hours), such as from sea level to 8,000 feet (2,400 m) as in many Colorado, USA mountain resorts. Stopping at an intermediate altitude overnight (for example, staying overnight when arriving through Denver, at 5,500 feet (1,700 m), when traveling to the aforementioned Colorado resorts) can alleviate or eliminate occurrences of AMS.[16]

Medications

The drug acetazolamide (trade name Diamox) may help some people making a rapid ascent to sleeping altitude above 2,700 metres (9,000 ft), and it may also be effective if started early in the course of AMS.[17] Acetazolamide can be taken before symptoms appear as a preventive measure at a dose of 125 mg twice daily. The Everest Base Camp Medical Centre cautions against its routine use as a substitute for a reasonable ascent schedule, except where rapid ascent is forced by flying into high altitude locations or due to terrain considerations.[18] The Centre suggests a dosage of 125 mg twice daily for prophylaxis, starting from 24 hours before ascending until a few days at the highest altitude or on descending;[18] with 250 mg twice daily recommended for treatment of AMS.[19] The Centers for Disease Control and Prevention (CDC) suggest the same dose for prevention of 125 mg acetazolamide every 12 hours.[20] Acetazolamide, a mild diuretic, works by stimulating the kidneys to secrete more bicarbonate in the urine, thereby acidifying the blood. This change in pH stimulates the respiratory center to increase the depth and frequency of respiration, thus speeding the natural acclimatization process. An undesirable side-effect of acetazolamide is a reduction in aerobic endurance performance. Other minor side effects include a tingle-sensation in hands and feet. Although a sulfonamide; acetazolamide is a non-antibiotic and has not been shown to cause life-threatening allergic cross-reactivity in those with a self-reported sulfonamide allergy.[21][22][23] Dosage of 1000 mg/day will produce a 25% decrease in performance, on top of the reduction due to high-altitude exposure.[24] The CDC advises that dexamethasone be reserved for treatment of severe AMS and HACE during descents, and notes that nifedipine may prevent HAPE.[20] Inhaled steroids have not been fund to be useful.[25]

A single randomized controlled trial found that sumatriptan may help prevent altitude sickness.[26] Despite their popularity, antioxidant treatments have not been found to be effective medications for prevention of AMS.[27] Phosphodiesterase inhibitors such as sildenafil has been limited by the possibility that they might worsen the headache of mountain sickness.[28]

Prior to the onset of altitude sickness, ibuprofen is a suggested non-steroidal anti-inflammatory and painkiller that can help alleviate both the headache and nausea associated with AMS. It has not been studied for the prevention of cerebral edema (swelling of the brain) associated with extreme symptoms of AMS.[29]

Oxygen

In high-altitude conditions, oxygen enrichment can counteract the hypoxia related effects of altitude sickness. A small amount of supplemental oxygen reduces the equivalent altitude in climate-controlled rooms. At 3,400 metres (11,200 ft) (67 kPa or 0.66 atm), raising the oxygen concentration level by 5% via an oxygen concentrator and an existing ventilation system provides an effective altitude of 3,000 m (10,000 ft) (70 kPa or 0.69 atm), which is more tolerable for those unaccustomed to high altitudes.[30]

Oxygen from gas bottles or liquid containers can be applied directly via a nasal cannula or mask. Oxygen concentrators based upon pressure swing adsorption (PSA), VSA, or vacuum-pressure swing adsorption (VPSA) can be used to generate the oxygen if electricity is available. Stationary oxygen concentrators typically use PSA technology, which has performance degradations at the lower barometric pressures at high altitudes. One way to compensate for the performance degradation is to utilize a concentrator with more flow capacity. There are also portable oxygen concentrators that can be used on vehicular DC power or on internal batteries, and at least one system commercially available measures and compensates for the altitude effect on its performance up to 4,000 m (13,000 ft). The application of high-purity oxygen from one of these methods increases the partial pressure of oxygen by raising the FiO2 (fraction of inspired oxygen).

Other methods

Increased water intake may also help in acclimatization[31] to replace the fluids lost through heavier breathing in the thin, dry air found at altitude, although consuming excessive quantities ("over-hydration") has no benefits and may cause dangerous hyponatremia.

Treatment

The only reliable treatment, and in many cases the only option available, is to descend. Attempts to treat or stabilize the patient in situ (at altitude) are dangerous unless highly controlled and with good medical facilities. However, the following treatments have been used when the patient's location and circumstances permit:

  • Oxygen may be used for mild to moderate AMS below 3,700 metres (12,000 ft) and is commonly provided by physicians at mountain resorts. Symptoms abate in 12 to 36 hours without the need to descend.
  • For more serious cases of AMS, or where rapid descent is impractical, a Gamow bag, a portable plastic hyperbaric chamber inflated with a foot pump, can be used to reduce the effective altitude by as much as 1,500 m (5,000 ft). A Gamow bag is generally used only as an aid to evacuate severe AMS patients, not to treat them at altitude.
  • Acetazolamide 250 mg twice daily dosing assists in AMS treatment by quickening altitude acclimatization.[32] A study by the Denali Medical Research Project concluded: "In established cases of acute mountain sickness, treatment with acetazolamide relieves symptoms, improves arterial oxygenation, and prevents further impairment of pulmonary gas exchange."[33]
  • The folk remedy for altitude sickness in Ecuador, Peru and Bolivia is a tea made from the coca plant. See mate de coca.
  • Steroids can be used to treat the symptoms of pulmonary or cerebral edema, but do not treat the underlying AMS.
  • Two studies in 2012 showed that Ibuprofen 600 milligrams three times daily was effective at decreasing the severity and incidence of AMS; it was not clear if HAPE or HACE was affected.[34][35]
  • Paracetamol (acetaminophen) has also shown to be as good as ibuprofen for altitude sickness when tested on climbers ascending Everest.[36]

Society and culture

Indigenous peoples of the Americas, such as the Aymaras of the Altiplano, have for centuries chewed coca leaves to try to alleviate the symptoms of mild altitude sickness. In Chinese and Tibetan traditional medicine an extract of the root tissue of Radix rhodiola is often taken in order to prevent the same symptoms. Neither of these therapies has proven effective in clinical study.

See also

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Ferri, Fred F. (2016). Ferri's Clinical Advisor 2017 E-Book: 5 Books in 1. Elsevier Health Sciences. p. 590. ISBN 9780323448383. Archived from the original on 22 December 2019. Retrieved 2 August 2018.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 "Altitude Diseases - Injuries; Poisoning". Merck Manuals Professional Edition. May 2018. Archived from the original on 27 June 2018. Retrieved 3 August 2018.
  3. 1 2 Simancas-Racines, D; Arevalo-Rodriguez, I; Osorio, D; Franco, JV; Xu, Y; Hidalgo, R (30 June 2018). "Interventions for treating acute high altitude illness". The Cochrane Database of Systematic Reviews. 6: CD009567. doi:10.1002/14651858.CD009567.pub2. PMC 6513207. PMID 29959871.
  4. 1 2 Meier, D; Collet, TH; Locatelli, I; Cornuz, J; Kayser, B; Simel, DL; Sartori, C (14 November 2017). "Does This Patient Have Acute Mountain Sickness?: The Rational Clinical Examination Systematic Review". JAMA. 318 (18): 1810–1819. doi:10.1001/jama.2017.16192. PMID 29136449. Archived from the original on 27 August 2021. Retrieved 4 December 2019.
  5. ↑ Weiss, Eric (2005). "Altitude Illness". A Comprehensive Guide to Wilderness & Travel Medicine - 3rd edition. pp. 137–141. ISBN 978-0-9659768-1-7. The Golden Rules of Altitude Illness 1) Above 8,000 feet, headache, nausea, shortness of breath, and vomiting should be considered to be altitude illness until proven otherwise. 2) No one with mild symptoms of altitude illness should ascend any higher until symptoms have resolved. 3) Anyone with worsening symptoms or severe symptoms of altitude illness should descend immediately to a lower altitude.
  6. ↑ West, John B. (2013). High Life: A History of High-Altitude Physiology and Medicine. Springer. pp. 2–7. ISBN 9781461475736. Archived from the original on 3 August 2018. Retrieved 3 August 2018.
  7. ↑ K. Baillie; A. Simpson. "Acute mountain sickness". Apex (Altitude Physiology Expeditions). Archived from the original on 1 February 2010. Retrieved 8 August 2007. — High altitude information for laypeople
  8. 1 2 3 A. A. R. Thompson. "Altitude Sickness". Apex. Archived from the original on 9 January 2010. Retrieved 8 May 2007.
  9. ↑ Douglas, Danielle; Robert Schoene (2010). "End-tidal partial pressure of carbon dioxide and acute mountain sickness in the first 24 hours upon ascent to Cusco, Peru (3326 meters)". Wilderness & Environmental Medicine. 21 (2): 109–113. doi:10.1016/j.wem.2010.01.003. PMID 20591371.
  10. 1 2 3 4 Auerbach, Paul (2007). Wilderness Medicine (5th ed.). Mosby Elsevier. ISBN 978-0-323-03228-5.
  11. ↑ FSF Editorial Staff (May–June 1997). "Wheel-well Stowaways Risk Lethal Levels of Hypoxia and Hypothermia" (PDF). Human Factors and Aviation Medicine. Flight Safety Foundation. 44 (3): 2. Archived (PDF) from the original on 28 November 2010. Retrieved 28 October 2010. The relative amount of oxygen in the air (21 percent) does not vary appreciably at altitudes up to 21,350 meters (70,000 feet).
  12. ↑ Hackett, P H; R C Roach (12 July 2001). "High-altitude illness". The New England Journal of Medicine. 345 (2): 107–114. doi:10.1056/NEJM200107123450206. ISSN 0028-4793. PMID 11450659.
  13. 1 2 3 4 Brown, James PR; Grocott, Michael PW (1 February 2013). "Humans at altitude: physiology and pathophysiology". Continuing Education in Anaesthesia Critical Care & Pain. 13 (1): 17–22. doi:10.1093/bjaceaccp/mks047. ISSN 1743-1816. Archived from the original on 12 October 2017. Retrieved 19 July 2017.
  14. ↑ Muza, S.R.; Fulco, C.S.; Cymerman, A. (2004). "Altitude Acclimatization Guide". U.S. Army Research Inst. Of Environmental Medicine Thermal and Mountain Medicine Division Technical Report (USARIEM–TN–04–05). Archived from the original on 23 April 2009. Retrieved 5 March 2009.
  15. ↑ Tortora, Gerard J.; Anagnostakos, Nicholas P. (1987). Principles of anatomy and physiology (Fifth ed.). New York: Harper & Row, Publishers. pp. 444–445. ISBN 978-0-06-350729-6.
  16. ↑ "Altitude Illness". Telluride, Colorado: Institute for Altitude Medicine. Archived from the original on 21 March 2017. Retrieved 21 March 2017.
  17. ↑ World Health Organization (1 January 2007). "Chapter 3: Environmental health risks". International travel and health (PDF). p. 31. Archived from the original (PDF) on 9 October 2009. Retrieved 21 November 2009.
  18. 1 2 "Prophylaxis". Everest BC Clinic, BaseCampMD.com. Archived from the original on 20 October 2018. Retrieved 21 November 2009.
  19. ↑ "Treating AMS". Everest BC Clinic, BaseCampMD.com. Archived from the original on 9 October 2018. Retrieved 21 November 2009.
  20. 1 2 Hackett P, Shlim D (2009). "Chapter 2 The Pre-Travel Consultation – Self-Treatable Diseases – Altitude Illness". In Turell D, Brunette G, Kozarsky P, Lefor A (eds.). CDC Health Information for International Travel 2010 "The Yellow Book". St. Louis: Mosby. ISBN 978-0-7020-3481-7. Retrieved 21 November 2009.
  21. ↑ Platt, D; Griggs RC (April 2012). "Use of acetazolamide in sulfonamide-allergic patients with neurologic channelopathies". Archives of Neurology. 69 (4): 527–9. doi:10.1001/archneurol.2011.2723. PMC 3785308. PMID 22158718.
  22. ↑ Kelly, TE; Hacket PH (2010). "Acetazolamide and sulfonamide allergy: a not so simple story". High Altitude Medicine & Biology. 11 (4): 319–23. doi:10.1089/ham.2010.1051. PMID 21190500.
  23. ↑ Lee, Andrew G; Randy Anderson; Randy H. Kardon; Michael Wall (July 2004). "Presumed "sulfa allergy" in patients with intracranial hypertension treated with acetazolamide or furosemide: cross-reactivity, myth or reality?". American Journal of Ophthalmology. 138 (1): 114–118. doi:10.1016/j.ajo.2004.02.019. PMID 15234289. Archived from the original on 27 August 2021. Retrieved 5 November 2013.
  24. ↑ "Altitude Acclimatization Guide" (PDF). Archived from the original (PDF) on 24 March 2012.
  25. ↑ Zhu, X; Liu, Y; Li, N; He, Q (August 2020). "Inhaled budesonide for the prevention of acute mountain sickness: A meta-analysis of randomized controlled trials". The American journal of emergency medicine. 38 (8): 1627–1634. doi:10.1016/j.ajem.2019.158461. PMID 31706656.
  26. ↑ Jafarian S.; Gorouhi F.; Salimi S.; Lotfi J. (2007). "Sumatriptan for prevention of acute mountain sickness: randomized clinical trial". Annals of Neurology. 62 (3): 273–277. doi:10.1002/ana.21162. PMID 17557349.
  27. ↑ Baillie JK, Thompson AA, Irving JB, Bates MG, Sutherland AI, Macnee W, Maxwell SR, Webb DJ (May 2009). "Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomised placebo-controlled trial". QJM. 102 (5): 341–348. doi:10.1093/qjmed/hcp026. PMID 19273551.
  28. ↑ Bates MG, Thompson AA, Baillie JK (March 2007). "Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema". Current Opinion in Investigational Drugs. 8 (3): 226–31. PMID 17408118.
  29. ↑ John Sanford (March 2012). "Ibuprofen decreases likelihood of altitude sickness, researchers find". Archived from the original on 24 April 2012. Retrieved 19 September 2012.
  30. ↑ West JB (February 1995). "Oxygen enrichment of room air to relieve the hypoxia of high altitude". Respiration Physiology. 99 (2): 225–232. doi:10.1016/0034-5687(94)00094-G. PMID 7777705.
  31. ↑ Dannen, Kent; Dannen, Donna (2002). Rocky Mountain National Park. Globe Pequot. p. 9. ISBN 978-0-7627-2245-7. Visitors unaccustomed to high elevations may experience symptoms of Acute Mountain Sickness (AMS)[...s]uggestions for alleviating symptoms include drinking plenty of water[.]{{cite book}}: CS1 maint: url-status (link)
  32. ↑ Cain SM, Dunn JE (July 1966). "Low doses of acetazolamide to aid accommodation of men to altitude". J Appl Physiol. 21 (4): 1195–200. doi:10.1152/jappl.1966.21.4.1195. PMID 5916650.
  33. ↑ Grissom CK, Roach RC, Sarnquist FH, Hackett PH (March 1992). "Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange". Annals of Internal Medicine. 116 (6): 461–5. doi:10.7326/0003-4819-116-6-461. PMID 1739236.
  34. ↑ Lipman, Grant S; Kanaan, Nicholas C; Holck, Peter S; Constance, Benjamin B; Gertsch, Jeffrey H (June 2012). "Ibuprofen prevents altitude illness: a randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories". Annals of Emergency Medicine. 59 (6): 484–490. doi:10.1016/j.annemergmed.2012.01.019. PMID 22440488.
  35. ↑ Gertsch, Jeffrey H; Corbett, B; Holck, Peter S; Mulcahy, A; Watts, M; et al. (2012). "Altitude Sickness in Climbers and Efficacy of NSAIDs Trial (ASCENT): randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness". Wilderness and Environmental Medicine. 23 (4): 307–315. doi:10.1016/j.wem.2012.08.001. PMID 23098412.
  36. ↑ Kanaan, Nicholas C.; Peterson, Alicia L.; Pun, Matiram; Holck, Peter S.; Starling, Jennifer; Basyal, Bikash; Freeman, Thomas F.; Gehner, Jessica R.; Keyes, Linda; Levin, Dana R.; O’Leary, Catherine J.; Stuart, Katherine E.; Thapa, Ghan B.; Tiwari, Aditya; Velgersdyk, Jared L.; Zafren, Ken; Basnyat, Buddha (1 June 2017). "Prophylactic Acetaminophen or Ibuprofen Result in Equivalent Acute Mountain Sickness Incidence at High Altitude: A Prospective Randomized Trial". Wilderness & Environmental Medicine. 28 (2): 72–78. doi:10.1016/j.wem.2016.12.011. ISSN 1080-6032. PMID 28479001. Archived from the original on 27 August 2021. Retrieved 6 February 2018.
Classification
External resources
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.